Generated from prompt:
Professional medical presentation for clinicians: Dyslipidaemia Management 2025 — Clinical Practice Update for Doctors, based on the 2025 ESC/EAS Guidelines. Focus on practical applications for physicians, not patients. Use a clean, bright hospital-style design (white background with medical blue accents). Include detailed charts and figures from the official ESC/EAS slides: 1) Classes of Recommendations, 2) Levels of Evidence, 3) LDL-C treatment goals (Figure 1), 4) LDL-lowering effects by therapy (Figure 2), 5) Lp(a) risk chart (Figure 3). Include slides on: title, objectives, risk stratification (SCORE2/SCORE2-OP), LDL-C targets by risk, treatment thresholds, pharmacologic therapy (statins, ezetimibe, PCSK9 inhibitors, bempedoic acid), lipid management in ACS, high triglycerides and Lp(a), HIV and oncology considerations, follow-up protocols, and key clinical takeaways for doctors.
Practical clinician guide to 2025 ESC/EAS dyslipidaemia guidelines. Covers SCORE2 risk strat, LDL-C targets/therapies (statins, PCSK9i, etc.), ACS protocols, triglycerides/Lp(a), HIV/oncology, follow-
This title slide is headed "Dyslipidaemia Management 2025." Its subtitle reads "Clinical Practice Update for Doctors based on 2025 ESC/EAS Guidelines."
Clinical Practice Update for Doctors based on 2025 ESC/EAS Guidelines
Source: 2025 ESC/EAS Guidelines
This agenda slide outlines a presentation on 2025 ESC/EAS lipid guidelines, beginning with risk stratification using SCORE2 tools and covering LDL-C targets, pharmacologic therapies like statins and PCSK9-i, and special cases such as ACS and HIV management. It concludes with follow-up protocols and key physician takeaways, referencing Figures 1-3.
2025 ESC/EAS overview, SCORE2/SCORE2-OP risk tools (Classes of Recs, Levels of Evidence).
Risk-based goals and treatment initiation criteria (Figure 1).
Statins, ezetimibe, PCSK9-i, bempedoic acid effects (Figure 2).
ACS, TG/Lp(a), HIV/oncology management (Figure 3).
Monitoring protocols and key messages for physicians. Source: Dyslipidaemia Management 2025 — Clinical Practice Update for Doctors
The slide outlines four classes of recommendations: Class I (strong, benefit >>> risk), IIa (reasonable, benefit >> risk), IIb (may be considered, benefit ≥ risk), and III (not recommended, no benefit or harm). It also details three levels of evidence: A (high, multiple RCTs/meta-analyses), B (moderate, single RCT/large observational), and C (low, expert consensus).
Benefit >>> Risk (Is recommended)
Benefit >> Risk (Should be considered)
Benefit ≥ Risk
No benefit or harm
Multiple RCTs or meta-analysis
Single RCT or large observational
Expert consensus Source: 2025 ESC/EAS Guidelines
SCORE2 estimates 10-year CVD risk for adults under 50 years, while SCORE2-OP targets older populations. These tools integrate dyslipidaemia assessment in primary prevention to guide lipid-lowering therapy intensity.
Source: 2025 ESC/EAS Guidelines
This slide presents LDL-C treatment goals stratified by cardiovascular risk levels. Very high-risk patients (ASCVD or equivalent) target <1.4 mmol/L, high-risk (SCORE2 ≥7.5%) <1.8 mmol/L, moderate-risk (SCORE2 5-7.4%) <2.6 mmol/L, and low-risk (<5%) <3.0 mmol/L.
ASCVD or equivalent
SCORE2 10-yr risk ≥7.5%
SCORE2 5-7.4% risk
SCORE2 <5% risk Source: ESC/EAS 2025 Guidelines
This table outlines LDL-C goals (mg/dL) and required reductions from baseline by cardiovascular risk category. Very high and high risk target <55 and <70 with ≥50% reduction, moderate <100 with ≥40%, and low <116 with lifestyle considerations.
{ "headers": [ "Risk Category", "LDL-C Goal (mg/dL)", "Reduction from Baseline" ], "rows": [ [ "Very high", "<55", "≥50%" ], [ "High", "<70", "≥50%" ], [ "Moderate", "<100", "≥40%" ], [ "Low", "<116", "Consider lifestyle" ] ] }
Source: 2025 ESC/EAS Guidelines (Figure 1)
The slide presents pharmacologic therapy options for LDL-C reduction, starting with high-intensity statins as first-line (50-60% reduction). It includes add-on ezetimibe (10-20% further lowering), injectable PCSK9 inhibitors (50-60% additional reduction), and oral bempedoic acid for statin-intolerant patients (15-25% reduction).
{ "features": [ { "icon": "💊", "heading": "High-Intensity Statins", "description": "First-line therapy; 50-60% LDL-C reduction (Figure 2)." }, { "icon": "🔗", "heading": "Add-on Ezetimibe", "description": "Additional 10-20% LDL-C lowering when statins alone insufficient." }, { "icon": "💉", "heading": "PCSK9 Inhibitors", "description": "Injectable option; potent 50-60% further LDL-C reduction." }, { "icon": "🧪", "heading": "Bempedoic Acid", "description": "Oral alternative; 15-25% LDL-C reduction for statin-intolerant patients." } ] }
Source: 2025 ESC/EAS Guidelines (Figure 2)
In ACS, start high-intensity statin (e.g., atorvastatin 80 mg) on day 1, add ezetimibe 1-4 weeks later if LDL-C >1.8 mmol/L, and escalate to PCSK9i at 3 months if still elevated despite combination therapy. Maintain triple therapy ongoing every 6-12 months to achieve LDL-C ≤1.4 mmol/L, emphasizing lifestyle and adherence.
{ "headers": [ "Step", "Timing", "Primary Therapy", "LDL-C Threshold / Target", "Notes" ], "rows": [ [ "1: Day 1", "Admission / Day 1", "High-intensity statin (e.g., atorvastatin 80 mg or rosuvastatin 20-40 mg)", "Initiate immediately", "Class I, LOE A; Max tolerated dose ASAP" ], [ "2: Early Assessment", "1-4 weeks post-statin", "Add ezetimibe 10 mg daily", "LDL-C >1.8 mmol/L on statin alone", "Combination therapy; recheck lipids" ], [ "3: Escalation", "3 months post-ACS", "Add PCSK9i (alirocumab/praluent or evolocumab/repatha)", "LDL-C >1.8 mmol/L despite statin + ezetimibe", "Very high-risk goal: ≤1.4 mmol/L (or ≥50% ↓ if 1.4-1.8)", "Class I, LOE A" ], [ "4: Maintenance", "Ongoing (q6-12 months)", "Maintain/maximize triple therapy if needed; consider bempedoic acid", "Achieve/maintain ≤1.4 mmol/L", "Lifestyle + pharmacologic; reassess adherence & safety" ] ] }
Source: 2025 ESC/EAS Dyslipidaemia Guidelines
For high triglycerides (>5 mmol/L), initiate fibrates (e.g., fenofibrate) or icosapent ethyl (4g/day) with lifestyle changes like low-carb diet and exercise, targeting <2.3 mmol/L while monitoring LFTs and myopathy. For elevated Lp(a) (>50 mg/dL), use Figure 3 for CVD risk assessment; if high-risk, consider emerging therapies like pelacarsen or olpasiran, plus statins for LDL-C.
| High Triglycerides (TG >5 mmol/L) | Elevated Lp(a) (>50 mg/dL) |
|---|---|
| Initiate fibrates (e.g., fenofibrate) or prescription omega-3 (icosapent ethyl 4g/day) to reduce TG and CV risk. Combine with lifestyle: low-carb diet, exercise, alcohol moderation. Monitor LFTs, myopathy; target TG <2.3 mmol/L. | Use Figure 3: Lp(a) risk chart for CVD risk assessment. If elevated + high risk (SCORE2), consider emerging therapies: pelacarsen (antisense), olpasiran (siRNA), or gene editors. Statins for concurrent LDL-C. |
Source: 2025 ESC/EAS Dyslipidaemia Guidelines
For HIV patients, statins are generally safe but simvastatin should be avoided with protease inhibitors, requiring close monitoring of drug interactions. In oncology, cardio-oncology management is essential, with lipid therapy restarted post-chemotherapy.
Source: 2025 ESC/EAS Guidelines
Follow-up protocols include assessing LDL-C, adherence, and side effects at 3-6 months, with labs timed 4-6 weeks post-therapy initiation. Therapy intensity should be adjusted per lipid response, and cardiovascular risk reassessed annually.
Source: 2025 ESC/EAS Dyslipidaemia Guidelines
The "Key Clinical Takeaways" slide prioritizes LDL-C reduction, personalized risk assessment via SCORE2/SCORE2-OP, early combo therapies for high-risk patients, and shared decision-making. It urges staying updated with ESC/EAS resources to elevate patient outcomes.
• Prioritize LDL-C reduction as primary target
Elevate Patient Outcomes
Source: 2025 ESC/EAS Dyslipidaemia Guidelines
Explore thousands of AI-generated presentations for inspiration
Generate professional presentations in seconds with Karaf's AI. Customize this presentation or start from scratch.